Abstract
Notably, fusion improved expression of chimeras relative to the TRAP or CSP components 23 alone. Immunization of BALB/c mice with the P. berghei TRAP-CSP fusion antigens formulated 24 in AddaVax adjuvant elicited antigen-specific antibody responses. Remarkably, fusion antigens 25 containing the CSP repeat region conferred complete sterile protection against P. berghei 26 sporozoite challenge, and furthermore, mice that survived the challenge were completely 27 protected from re-challenge 16 weeks after the first challenge. In contrast, fusion antigens 28 lacking the CSP repeat region were less effective, indicating that the CSP repeat region 29 provided enhanced protection, which correlated with higher antibody titers elicited by fusion 30 antigens containing the CSP repeat region. In addition, we demonstrated that N-linked glycans 31 had no significant effect on antibody elicitation or protection. Our results show that TRAP-CSP 32 fusion antigens could be highly effective vaccine candidates. Our approach provides a platform
Introduction

36
Malaria remains a global health problem with an estimated 216 million cases of infection 37 and 445,000 deaths worldwide in 2016. Children under age 5 are most vulnerable to malaria 38 infection and suffer high mortality. The most advanced vaccine, RTS,S, reduced infection by 39 27% in infants and 46% in children during the first 18 months, and protection declined thereafter 40 [1, 2], leaving an unmet need for more effective vaccines. 41 Malaria is caused by Plasmodium parasites transmitted by Anopheles mosquitoes. 42 Infected mosquitoes introduce salivary gland sporozoites into the host during a blood meal. Two major proteins on the surface of sporozoites, the circumsporozoite protein (CSP) 52 and thrombospondin-related adhesion protein (TRAP), are the focus of pre-erythrocytic subunit 53 vaccine development; both are essential for sporozoite motility and liver-stage infection [7, 8] . 54 CSP, the most abundant surface protein in sporozoites, is composed of an N-terminal domain 55 (NTD), Region I (RI), where CSP is cleaved during cell invasion [9, 10], a central repeat region, 56 and the C-terminal TSR domain followed by a glycosylphosphatidylinositol (GPI) membrane 57 anchor ( Fig 1A) . The RTS vaccine includes the C-terminal portion of the repeat region (R) and 58 the TSR domain (T) from P. falciparum CSP (Fig 1A) However, immunological interference has been a concern when combining two vaccines. Blotting to PVDF membrane was carried out using Tran-Blot Turbo transfer system (Bio-RAD).
153
Membrane was probed with 0.4 µg/ml primary antibody, followed by incubation with HRP-154 conjugated 2 nd antibodies and chemiluminescence imaging using LAS-4000 system (Fuji Film).
155
ImageJ software was used for quantitation of protein bands. structures and regions containing protective B and T-cell epitopes from both proteins (Fig 1B) . 211 The folded VWA and TSR domains at the N-terminus of TRAP [18] and the TSR domain at the 212 C-terminus of CSP [22] were left intact in all fusion constructs, which varied in their content of 213 CSP repeats in between the folded domains (Fig 1B) . The VWA and TSR domains of TRAP are (Fig 1D, top, lane 4 and 6, and lanes 10 and 12) . However, a weak P. falciparum CSP-RT 251 band of ~27 kD was detected by repeat region antibody 2A10 under reducing condition (Fig 1D,   252 bottom, lane 6). In contrast to TRAP and CSP fragments alone, larger amounts of TRAP-CSP 253 fusion proteins of both P. berghei and P. falciparum were detected by the His tag antibody and 254 had the expected sizes (Fig 1C top, lanes 8 and 9 vs 7; Fig 1D top PfTRAP-N. Additionally, the chimeras containing the CSP repeat region were recognized by 259 CSP repeat region antibodies (Fig 1C and 1D, bottom) . Thus, fusion improved expression of the 260 chimeric proteins relative to the TRAP or CSP components alone. on the surface of transfectants (Fig s2, Table s1 ) and stained unfixed P. falciparum sporozoites 285 (Fig s3, Table s1 ), suggesting that they recognize native epitopes. Furthermore, the epitopes of 286 mAbs CL2/1, CL5/27, CL5/22, CL5/46 and CL5/54 are sensitive to disulfide reduction (Fig s5) . TSR domain and -ribbon at levels comparable to the TRAP-N alone (Fig 3A) . Furthermore, the were comparable to the TRAP-N/CSP-RT (dNG) antigen group, at all three time points (Fig 4A) . 321 Similarly, no significant differences in antibody titers were observed between the TRAP-N/CSP-322 T and TRAP-N/CSP-T (dNG) groups (Fig 4A and 4B) . The results showed that the four putative (Fig 4A) . By comparison, antibody titers against the TRAP-N/CSP-T protein 339 lacking the repeat region were comparable among the four groups of mice (Fig 4B) . (Table I ). In contrast, the 2 mice each immunized with TRAP-N/CSP-T and TRAP-N/CSP-T
360
(dNG) antigens that were protected at week 16 were not protected at week 32 and showed 361 blood stage infection (Table I) . identified potent protective and "dual specificity" antibodies to Pf CSP bind to the NANP repeats 444 and the junction (J) region [32, 33] . This region has not been included in our P. berghei 445 constructs or RTS,S. However, the P. falciparum chimeric construct containing this region,
446
TRAP-N/CSP-JRT, was expressed even better than the TRAP-N/CSP-RT construct (Fig 1D) . It 
